Paediatric HIV Drug Resistance in African Settings
|
|
- Austen Norman
- 8 years ago
- Views:
Transcription
1 Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia
2 Background: ART for children in sub- Saharan Africa 2.3 million children with HIV Treatment coverage estimated at 26% for Africa; 32% for Eastern and Southern Africa 2
3 HIVDR: Predisposing factors in children Exposure to antiretroviral medication for PMTCT Extended Nevirapine/Zidovudine Single dose nevirapine Higher baseline viral loads, longer time to suppression Inappropriate dosing because of limited paediatric formulations and weight changes Limited training of HCW in pediatric management 3 Adherence issues Reliance on adult caretakers Poorly palatable formulations (esp. liquids)
4 Pediatric HIVDR: extra challenges Life-long treatment with very limited number of regimens available HIVDR monitoring initiatives in Africa have limited pediatric cohorts
5 Countries showing resistance data in the HIV-1- infected paediatric population Rojas Sánchez P, and Holguín A J. Antimicrob. Chemother. 2014;jac.dku104
6 Resistance studies in HIV-1-infected paediatric populations over time including naive and pretreated patients Although majority of HIV infected children live in Sub Saharan Africa, HIVDR data in children only available in 11 (20.7%) of the 53 African countries Rojas Sánchez P, and Holguín A J. Antimicrob. Chemother. 2014;jac.dku104
7 Summary of TDR rates in drug-naive HIV-1-infected paediatric populations Country Sampling Period Naive Children Age Range Subjects with Resistance mutations to (%) NNRTI NRTI PI 2 Classes Cameroon Uganda Uganda (MARCH) Nigeria (MARCH) African countries out of 15 worldwide reporting TDR rates
8 HIVDR after treatment Monitoring initiatives in Africa have limited pediatric cohorts and mainly small numbers Published data Uganda(4), Mozambique (2), Camerron, Senegal, Kenya (2), South Africa, Ivory Coast, Malawi and Mali High proportion of children with drug-resistant HIV-1 infections after first-line ART failure in resource-limited settings (Sigaloff, Lancet Inf Dis 2011) Prevalence rates very variable NRTI 0-100%, NNRTI 0-100%, PI 0-37%, NRTI & NNRTI 0-100% NNRTI resistance most common: K103N, Y181C NRTI: M184V en TAMs 8 PI: only in certain regions (South America, South Africa)
9 Monitoring Emerging HIVDR and Associated Factors in Sentinel ART Sites Cohorts of approximately 130 ART-naive individuals beginning ART followed for 12 months Baseline assessment of HIVDR: Genotyping, ARV history 12-month assessment of HIVDR: Status (lost to follow-up, stop, switch, still on first-line ART) Viral load + genotyping at 12 months if still on first-line ART, or at regimen switch
10 have applied for WHO accreditation Implementation of the HIVDR strategy Country HIVDR WG 5yr plans EWI Surveys of Emerging Resistance HIVDR- Transmission TS HIVDR database Zimbabwe Accredited genotyping laboratories Zambia Kenya Malawi South Africa Tanzania Ethiopia Mozambique Paediatric Uganda Paediatric Namibia Paediatric Swaziland Paediatric Botswana
11 Single-dose NVP When prophylaxis fails, NNRTI resistance in up to 60% of infants < 6m (Hunt, AIDS 2011) Children with NVP exposure are less likely to achieve virological suppression on NNRTI-based regimens (Musiime AIDS Res Hum Retroviruses 2009) 11
12 Pediatric HIVDR after PMTCT Zimbabwe 232 children <18m Swaziland 201 children <18m Ugandan data underestimate pediatric HIVDR as compared to 100% PMTCT studies with younger children elsewhere in Africa Silvia Bertagnolio, Bloemfontein HIVDR workshop November, 2013
13 Treatment after PMTCT Virological failure after 24 weeks of AZT, 3TC, LPV/r vs. AZT, 3TC, NVP: 21.7% vs. 39.6% (Palumbo, N Eng J Med 2010) Baseline resistance to nevirapine was predictive of treatment failure Protease inhibitor preferred to nevirapine in children with exposure to single dose nevirapine 13
14 MARCH-Uganda study Prospective cohort study of 360 children in Uganda on ART PASER junior ART initiation or switch ~75% first-line ~15% second-line ARV-naive PMTCT
15 MARCH - objectives - Measure baseline HIVDR prevalence in children initiating first- or second-line ART - Monitor virological response to treatment - Determine prevalence and patterns of HIVDR in children with detectable viral load - Identify risk factors for virologic failure and HIVDR
16 Study design Prospective, observational cohort study of 120 HIV positive children 12 years of the 3 JCRC sites Eligible when initiating first-line ART or switching to second-line ART due to treatment failure Follow-up 2 years, VL testing every 6 months HIVDR test if VL >1000 copies/ml at Reference Laboratory in Kampala
17 MARCH (sub-)study results Research question: What are the factors influencing the timing of pediatric ART initiation? Methods Both quantitative and qualitative data analysis 17
18 18 Baseline characteristic of children initiating first-line ART
19 HIVDR among children initiating first-line ART % Any mutation NRTI NNRTI 2-class 0 First-line (n=279) ARV-naive (n=233) ARV-exp (n=46) 19 Frequencies (%) of HIVDR mutations in patients initiating firstline treatment either ARV-naïve or with previous PMTCT (n=14) or unknown exposure status (n=32)
20 HIVDR among ARV-naïve children initiating first-line ART, per site 20 Frequencies (%) of HIVDR mutations in ARV-naïve children initiating first-line treatment at the three JCRC sites.
21 Resistance patterns before first-line ART initiation 21
22 22 Factors associated with HIVDR before first-line ART initiation
23 Resistance in children switching to secondline ART 50 children enrolled in MARCH at time of failure of NNRTI-based first-line ART: 29 in Kampala, 18 in Mbale, 3 in Fort Portal Baseline characteristics: Median age (IQR), years 5.5 ( ) WHO clinical stage 3 or 4 23 (46%) PMTCT-exposure 13 (26%) Median duration of first-line ART, months 29.8 ( ) 1 previous ART regimen 24 (48%) Last ( failing ) ART regimen AZT+3TC+EFV/NVP 35 (70%) Triomune 10 (20%) 23 ABC-containing 5 (10%)
24 24 Resistance patterns at switch (n=44)
25 MARCH-Uganda: Susceptibility to RTinhibitors at time of switch Predicted HIV susceptibility to nucleoside and nonnucleoside reverse transcriptase inhibitors in children with first-line antiretroviral therapy failure (n = 44) 25 Sigaloff et al, AIDS research and human
26 Resistance patterns at switch TAM-2 pathway preferred? 26
27 Conclusions Important barriers to care remain for children, accounting for< 35% ART coverage in most African regions Even among reportedly ARV-naïve children, drug-resistant virus was present in 8% (MARCH) Besides PMTCT exposure, maternal ART use and breastfeeding may be important risk factors for baseline HIVDR The PMTCT practices of the last decade (non-use of Maternal HAART) have contributed to early virologic failure. The use of Maternal HAART scale up needs to be monitored for pediatric HIVDR
28 Conclusions Extensive resistance at switch (46% multiple TAMs) due to delayed switching fear of exhausting treatment options in children? These high HIVDR rates necessitate continued national surveillance programs to monitor trends. Affordable viral load & drug resistance testing and improved access to alternative combinations of ARVs are urgently needed
29 Acknowledgements All participants and their parents/caregivers JCRC, Uganda Cissy Kityo Peter Mugyenyi Victor Musiime Joshua Kayiwe Elizabeth Khauda Lillian Nakatudde Andrew Mukuye Bernard Ayebazibwe Michael Owor European Developing Countries Trial Partnership PharmAccess, AIGHD, AMC Tobias Rinke de Wit Kim Sigaloff Job Calis Sonia Boender Raph Hamers Sibyl Geelen Michèle van Vugt Michael Boele van Hensbroek University Medical Center, Utrecht Rob Schuurman 29 World Health Organization (WHO) Sylvia Bertagnolio
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa T. Sonia Boender; Raph L. Hamers; Pascale Ondoa; Maureen Wellington; Cleophas Chimbetete; Margaret Siwale; Eman E F
More informationTheonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
More informationAntiretroviral therapy for HIV infection in infants and children: Towards universal access
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
More informationSURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV
SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV SURVEY REPORT AIDS & TB UNIT Ministry Of Health And Child Welfare Zimbabwe December 2012 1 Table
More informationThe World Health Organization s global strategy for prevention and assessment of HIV drug resistance
The World Health Organization s global strategy for prevention and assessment of HIV drug resistance Diane E Bennett 1 *, Silvia Bertagnolio 1, Donald Sutherland 2 and Charles F Gilks 1 1 World Health
More informationHIV DRUG RESISTANCE EARLY WARNING INDICATORS
HIV DRUG RESISTANCE EARLY WARNING INDICATORS World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update ACKNOWLEDGEMENTS The preparation
More informationHIV Drug resistanceimplications
HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:
More informationAids Fonds funding for programmes to prevent HIV drug resistance
funding for programmes to prevent HIV drug resistance Call for proposals July 2012 Page 1 van 10 grants@aidsfonds.nl Documentnumber 20120719/JKA/RAP Universal Access Lifting barriers to universal access
More informationClinical rationale for viral load testing
Clinical rationale for viral load testing Francois Venter Wits Reproductive Health & HIV Institute Caveats I m a believer in VLs My talk looks at resource poor environments Why do we need a rationale???
More informationWorld Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites
World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites Michael R Jordan 1 *, Diane E Bennett 2, Silvia Bertagnolio
More informationSurveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania
Antiviral Therapy 13 Suppl 2:77 82 Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania Geofrey R Somi 1, Tabitha Kibuka 2, Karidja Diallo
More informationChapter 3 South African guidelines and introduction to clinical cases
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
More informationTreating HIV in children with tuberculosis
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
More informationThe Basics of Drug Resistance:
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
More informationPaediatric HIV treatment update
Paediatric HIV treatment update James Nuttall Red Cross War Memorial Children s Hospital & University of Cape Town ART Resistance & New Treatment Options 6 th FIDSSA Conference, 5-7 November 2015 ART Eligibility
More informationCombination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
More informationThe studies reported in this thesis were performed at the department of Viroscience of the Erasmus Medical Center, Rotterdam, the Netherlands.
The studies reported in this thesis were performed at the department of Viroscience of the Erasmus Medical Center, Rotterdam, the Netherlands. This research was supported by the Aids Fonds, Netherlands
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationTreatment Action Campaign UNDETECTABLE HOW VIRAL LOAD MONITORING CAN IMPROVE HIV TREATMENT IN DEVELOPING COUNTRIES. www.msfaccess.
Treatment Action Campaign UNDETECTABLE HOW VIRAL LOAD MONITORING CAN IMPROVE HIV TREATMENT IN DEVELOPING COUNTRIES www.msfaccess.org Table of Contents 3 Executive Summary 4 Introduction 5 MSF HIV/AIDS
More informationLaboratory Challenges to Viral Load Implementation in Resource-Limited Settings. 5 May, 2014 Lusaka, Zambia
Laboratory Challenges to Viral Load Implementation in Resource-Limited Settings 5 May, 2014 Lusaka, Zambia Many African countries are considering greater viral load use in public ART programs Mali Viral
More informationFinancing Education for All in Sub Saharan Africa: Progress and Prospects
Financing Education for All in Sub Saharan Africa: Progress and Prospects Albert Motivans Education for All Working Group Paris, 3 February 211 1 Improving the coverage and quality of education finance
More informationGlobal Update on HIV Treatment 2013: Results, Impact and Opportunities
June 2013 Global Update on HIV Treatment 2013: Results, Impact and Opportunities WHO/UNAIDS/UNICEF v2 Outline Results: Progress towards Global Targets - Antiretroviral treatment - Prevention of mother-to-child
More informationTreatment Action Campaign UNDETECTABLE HOW VIRAL LOAD MONITORING CAN IMPROVE HIV TREATMENT IN DEVELOPING COUNTRIES. www.msfaccess.
Treatment Action Campaign UNDETECTABLE HOW VIRAL LOAD MONITORING CAN IMPROVE HIV TREATMENT IN DEVELOPING COUNTRIES www.msfaccess.org Table of Contents 3 Executive Summary 4 Introduction 5 MSF HIV/AIDS
More informationExpanding access to viral load monitoring in resource-limited settings
Meeting report Expanding access to viral load monitoring in resource-limited settings IAS-ILF Symposium at INTEREST 2014 5 May 2014 - Lusaka, Zambia Acknowledgements This report is the result of a symposium
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationSwitch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Gaetana Sterrantino Azienda Ospedaliero-Universitaria Careggi Infectious diseases, Florence, Italy Background
More informationReview The status of HIV-1 resistance to antiretroviral drugs in sub-saharan Africa
Antiviral Therapy 13:625 639 Review The status of HIV-1 resistance to antiretroviral drugs in sub-saharan Africa Raph L Hamers 1 *, Inge Derdelinckx 2, Michèle van Vugt 1,3, Wendy Stevens 4, Tobias F Rinke
More informationSURVEILLANCE OF TRANSMITTED HIV DRUG RESISTANCE AMONG VOLUNTARY COUNSELING AND TESTING CENTERS IN GONDAR TOWN ETHIOPIA
SURVEILLANCE OF TRANSMITTED HIV DRUG RESISTANCE AMONG VOLUNTARY COUNSELING AND TESTING CENTERS IN GONDAR TOWN ETHIOPIA ETHIOPIAN PUBLIC HEALTH INSTITUTE 2014 PREFACE Ethiopia has been progressively expanding
More informationHow To Get Rid Of Hiv
ACCESS TO ANTIRETROVIRAL THERAPY IN AFRICA STATUS REPORT ON PROGRESS TOWARDS THE 2015 TARGETS EARLY INITIATION OF ANTIRETROVIRAL THERAPY IS CRUCIAL TO THE AIDS RESPONSE Achieving the vision of zero new
More informationShort Communication: Transmitted HIV Drug Resistance in Antiretroviral-Naive Pregnant Women in North Central Nigeria
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 30, Number 2, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/aid.2013.0074 Short Communication: Transmitted HIV Drug Resistance in Antiretroviral-Naive Pregnant
More informationACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
More informationFARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS Stefano Vella Dipartimento del Farmaco Istituto Superiore di Sanità - Roma Stages of HIV-1 Life Cycle Targeted by Anti-HIV Drugs In: Gulick RM, Topics HIV
More informationLondon Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
More informationGoal 6: Combat HIV/AIDS, malaria and other diseases
Goal 6: Combat HIV/AIDS, malaria and other diseases Africa s progress in the fight against HIV/AIDS, TB and malaria is being sustained even stepped up. This is noteworthy as there are worrying signs of
More informationGlobal Update on HIV Treatment 2013: Results, Impact and Opportunities. HIV treatment
EMBARGO: till 12:00 noon, Kuala Lumpur time; 04:00 am GMT, 30 June 2013 HIV treatment Global Update on HIV Treatment 2013: Results, Impact and Opportunities June 2013 WHO Library Cataloguing-in-Publication
More informationPoster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA
Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA D Armenia 1, M Zaccarelli 2, V Borghi 3, W Gennari 3, A Giannetti
More informationConsolidated guidelines on the use of antiretroviral drugs for treating
TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
More informationS P. The Goals Model as a Tool for Allocating HIV/AIDS Resources & Strategic Planning
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P The Goals Model as a Tool for Allocating HIV/AIDS Resources & Strategic Planning How do the Tools Fit? Surveillance
More informationHIV/AIDS IN SUB-SAHARAN AFRICA: THE GROWING EPIDEMIC?
HIV/AIDS IN SUB-SAHARAN AFRICA: THE GROWING EPIDEMIC? Paul Bennell 1 It is widely believed that the AIDS epidemic continues to spread rapidly throughout the African continent with rising levels of HIV
More informationEACS 2013. Dominique Braun Universitätsspital Zürich
EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir
More informationReference: NHS England B06/P/a
Clinical Commissioning Policy: Dolutegravir for treatment of HIV- 1 in adults and adolescents Reference: NHS England B06/P/a 1 NHS England Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1
More informationThe Rapidly Evolving Regulatory Landscape in Africa
The Rapidly Evolving Regulatory Landscape in Africa B. Dicky Akanmori Regional Advisor, Vaccine Regulation Immunization, Vaccines & Emergencies Cluster What has changed? Prime targets for vaccine development
More informationUPDATE UNAIDS 2016 DATE 2016
GLOBAL AIDS UP GLOBAL AIDS UPDATE UNAIDS 2016 DATE 2016 ENORMOUS GAINS, PERSISTENT CHALLENGES The world has committed to ending the AIDS epidemic by 2030. How to reach this bold target within the Sustainable
More informationPEPFAR/CDC Site Monitoring System Goal and Objectives
PEPFAR/CDC Site Monitoring System Goal and Objectives Goal: To standardize clinical site quality monitoring by PEPFAR/CDC in-country staff through assessment and scoring of site performance on key program
More informationScreening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
More informationAntiretroviral Treatment
Antiretroviral Treatment Michael A. Tolle, MD, MPH Heidi Schwarzwald, MD, MPH Nancy R. Calles, MSN, PNP, ACRN, MPH Objectives 1. Discuss the goals of treatment for human immunodeficiency virus (HIV) infection.
More informationPermission to reproduce any part of this publication will be freely granted to educational and non-profit organizations.
Towards an AIDS-free generation Children and AIDS Sixth Stocktaking Report, 2013 UNITE FOR CHILDREN UNITE AGAINST AIDS Stocktaking reports on children and AIDS are the flagship publications of the Unite
More informationTable 5: HIV/AIDS statistics for Africa (excluding North Africa), 2001 and 2009
Table 5: HIV/AIDS statistics for Africa (excluding North Africa), 2001 and 2009 Year People living with HIV (million) People newly infected with HIV (million) Children living with HIV (million) AIDS-related
More informationRegister for e-mail notification of guideline updates at http://aidsinfo.nih.gov/e-news.
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Visit the AIDSinfo website
More informationHIV/AIDS Programme WHO HIV DRUG RESISTANCE REPORT 2012
HIV/AIDS Programme WHO HIV DRUG RESISTANCE REPORT 2012 HIV/AIDS Programme WHO HIV DRUG RESISTANCE REPORT 2012 WHO Library Cataloguing-in-Publication Data The HIV drug resistance report - 2012. 1.Anti-HIV
More informationLow level viremia and HIV-1 drug resistance in patients with virological rebound after suppression with a first line antiretroviral regimen
Low level viremia and HIV-1 drug resistance in patients with virological rebound after suppression with a first line antiretroviral regimen Manuela Colafigli Catholic University of S. Heart Rome, Italy
More informationJanssen Global Public Health: HIV Medicines Access & Partnerships Program APRIL 2014. Julius Bustamante, Pajaros
Julius Bustamante, Pajaros Artwork from Hospital Audiences, Inc. (HAI), a nonprofit organization that inspires healing, growth and learning through access to the arts for the culturally underserved. Janssen
More informationGUIDANCE ON GLOBAL SCALE-UP OF THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV
GUIDANCE ON GLOBAL SCALE-UP OF THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV Towards universal access for women, infants and young children and eliminating HIV and AIDS among children with The
More informationChapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013 VERSION 14 March 2013 Contents Acronym glossary... 2 1. Goals of the programme... 3 2. Objectives... 3 3. Specific Objectives... 3 4. Adults and
More informationMonitoring of HIV positive mothers and HIV exposed infants in context of Option B+ implementation
Monitoring of HIV positive mothers and HIV exposed infants in context of Option B+ implementation Kenya Outline of the presentation Background: Kenya in Context PMTCT Program progress 2012-2015 Option
More informationRAPID ASSESSMENT OF PEDIATRIC HIV TREATMENT IN NIGERIA
RAPID ASSESSMENT OF PEDIATRIC HIV TREATMENT IN NIGERIA JANUARY 2013 This publication was made possible through the support of the U.S. President s Emergency Plan for AIDS Relief (PEPFAR) through the U.S.
More informationThe Botswana Combination Prevention Project (BCPP)
The Botswana Combination Prevention Project (BCPP) The Next Phase of HIV Prevention in Botswana A collaboration between MoH CDC-Botswana, HSPH-BHP Presenter: M.J. Makhema NAC 4 th September 2012 Mashi
More informationHBV screening and management in HIV-infected children and adolescents
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationA 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping
A 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping Cynthia J. Carlyn, MD * Aldona L. Baltch, MD * Marty H. St. Clair, BS Mary J. George, PhD * Raymond P. Smith,
More informationEuropean Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update
AIDS Rev. 2011;13:77-108 Anne-Mieke Vandamme, et al.: European HIV Drug Resistance Guidelines European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update Anne-Mieke Vandamme
More informationAIO Life Seminar Abidjan - Côte d Ivoire
AIO Life Seminar Abidjan - Côte d Ivoire Life Insurance Market Survey of Selected African Countries Bertus Thomas Africa Committee of the Actuarial Society of South Africa Agenda SECTION 1 SURVEY OBJECTIVE
More informationHPTN 073: Black MSM Open-Label PrEP Demonstration Project
HPTN 073: Black MSM Open-Label PrEP Demonstration Project Overview HIV Epidemiology in the U.S. Overview of PrEP Overview of HPTN HPTN 061 HPTN 073 ARV Drug Resistance Conclusions Questions and Answers
More informationDOI: 10.1111/hiv.12217 on behalf of British HIV Association. HIV Medicine (2015) ORIGINAL RESEARCH
DOI: 10.1111/hiv.12217. ORIGINAL RESEARCH Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult
More informationHIV/AIDS Programme MEETING REPORT ON WHO RESNET ANNUAL MEETING 4 MARCH 2012 BILL AND MELINDA GATES FOUNDATION, SEATTLE, USA
HIV/AIDS Programme MEETING REPORT ON WHO RESNET ANNUAL MEETING 4 MARCH 2012 BILL AND MELINDA GATES FOUNDATION, SEATTLE, HIV/AIDS Programme MEETING REPORT ON WHO RESNET ANNUAL MEETING 4 MARCH 2012 BILL
More informationWHO/HIVRESNET HIV DRUG RESISTANCE LABORATORY STRATEGY
WHO/HIVRESNET HIV DRUG RESISTANCE LABORATORY STRATEGY JULY, 2010 1 Table of Contents Abbreviations... 4 1. WHO/HIVResNet Global HIV Drug Resistance Strategy... 5 1.1. NATIONAL HIVDR WORKING GROUP...6 1.2.
More informationWorld AIDS Day: Most African governments win high marks for efforts to fight HIV/AIDS
Dispatch No. 5 1 December 2014 World AIDS Day: Most African governments win high marks for efforts to fight HIV/AIDS Afrobarometer Dispatch No. 5 Samantha Richmond, Carolyn Logan, and Brian Howard Summary
More informationHIV. Head - Paediatric HIV Treatment Programmes. Right to Care. Dr Leon Levin
HIV Dr Leon Levin Head - Paediatric HIV Treatment Programmes Right to Care Disclaimer This talk represents my personal experience in managing teenagers with HIV over the last 14 years. It does not purport
More informationSession 4: The Drug Management Cycle: Selection. David Peters
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More information2013 Report on Costs of Treatment in the President s Emergency Plan for AIDS Relief (PEPFAR)
2013 Report on Costs of Treatment in the President s Emergency Plan for AIDS Relief (PEPFAR) Background The rapid expansion of access to antiretroviral treatment (ART) under PEPFAR has been one of the
More informationRoutine HIV Monitoring
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
More informationHIV Reports. Antiretroviral Stewardship in a Pediatric HIV Clinic. Development, Implementation and Improved Clinical Outcomes
HIV Reports Antiretroviral Stewardship in a Pediatric HIV Clinic Development, Implementation and Improved Clinical Outcomes Alice J. Hsu, PharmD, BCPS, AQ-ID,* Asha Neptune, MA, MPH, Constants Adams, BS,
More informationHIV Guidelines. New Strategies.
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
More informationGARPR Online Reporting Tool
GARPR Online Reporting Tool 0 Narrative Report and Cover Sheet 1) Which institutions/entities were responsible for filling out the indicator forms? a) NAC or equivalent Yes b) NAP Yes c) Others Yes If
More informationAntiretroviral Drugs in the Treatment and Prevention of HIV Infection
Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev, MD Uses of Antiretroviral Agents Treatment of chronic HIV infection Prevention of mother-to-child transmission [PMTCT]
More informationThe Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact
The Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact April 2013 Executive Summary Over the last five years, the results of Global Fund-supported
More informationHIV and Infant Cancer - An Empirical Research
Need for Timely Paediatric HIV Treatment within Primary Health Care in Rural South Africa Graham S. Cooke 1,2 *, Kirsty E. Little 3, Ruth M. Bland 1,4, Hilary Thulare 1, Marie-Louise Newell 1,3 1 Africa
More information2015-10-26 10:58 FOR UK AND EMEA MEDICAL MEDIA ONLY. (Logo: http://photos.prnewswire.com/prnh/20140324/ny88746logo)
2015-10-26 10:58 Janssen Receives Positive CHMP Opinion Recommending EDURANT(R)Black Triangle Drug (rilpivirine) for the Treatment of Adolescents Aged 12 to
More informationHIV/AIDS Prevention and Care
HIV/AIDS Prevention and Care Nancy S. Padian, PhD, MPH Professor, Obstetrics, Gynecology & Reproductive Sciences Associate Director for Research, Global Health Sciences and AIDS Research Institute: University
More informationAmin Khademi 1, R. Scott Braithwaite 2,3, Denis Saure 4, Andrew J. Schaefer 5, Kimberly Nucifora 3, Mark S. Roberts 5,6,7 * Abstract
Should Expectations about the Rate of New Antiretroviral Drug Development Impact the Timing of HIV Treatment Initiation and Expectations about Treatment Benefits? Amin Khademi 1, R. Scott Braithwaite 2,3,
More informationDie Toronto Konferenz. K. Arasteh Auguste-Viktoria-Klinikum
Die Toronto Konferenz K. Arasteh Auguste-Viktoria-Klinikum Subjektive Schwerpunkte Medizinische Prävention Monotherapie CD4 guided treatment interuption (CD4-TI) HIV Prävention (Gita Ramjee) Rationale
More informationNICHD s Pediatric, Adolescent, & Maternal AIDS Branch
Friends of NICHD Webinar: NICHD s Pediatric, Adolescent, & Maternal AIDS Branch Lynne Mofenson, MD Branch Chief December 19, 2008 Please call in-dial: 888-517-2197 Code:7080363 Webinar Guidelines All participants
More informationViral load testing. medical monitoring: viral load testing: 1
medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the
More informationREVERSING HIV/AIDS? HOW ADVANCES ARE BEING HELD BACK BY FUNDING SHORTAGES
REVERSING HIV/AIDS? HOW ADVANCES ARE BEING HELD BACK BY FUNDING SHORTAGES Over ten years after Médecins Sans Frontières (Doctors Without Borders, or MSF) began providing antiretroviral treatment to a limited
More informationEffectiveness of PMTCT programs in Sub-Saharan Africa, a meta-analysis
Effectiveness of PMTCT programs in Sub-Saharan Africa, a meta-analysis Umeå International School of Public Health Epidemiology and Global Health Umeå University 2012 By Daniel Adane Supervisor John Kinsman
More informationA HISTORY OF THE HIV/AIDS EPIDEMIC WITH EMPHASIS ON AFRICA *
UN/POP/MORT/2003/2 5 September 2003 ENGLISH ONLY WORKSHOP ON HIV/AIDS AND ADULT MORTALITY IN DEVELOPING COUNTRIES Population Division Department of Economic and Social Affairs United Nations Secretariat
More informationClinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults
Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Reference: NHS England B06/P/x 1 Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults
More informationPrevention of mother-to-child transmission of HIV/AIDS programmes
CHAPTER 7 III Prevention of mother-to-child transmission of HIV/AIDS programmes Lily Kak, Inam Chitsike, Chewe Luo, Nigel Rollins Each year, over half a million newborns are infected with HIV in sub-saharan
More informationDecision Analysis Example
Options for Doing Cost-Effectiveness Analysis Decision Analysis Example after Occupational Exposure to Clinical trial Mathematical modeling Clinical Trial Incremental Cost-Effectiveness Ratio Conduct a
More information1 Appendix B: DESCRIPTION OF HIV PROGRESSION SIMULATION *
1 Appendix B: DESCRIPTION OF HIV PROGRESSION SIMULATION * Our simulation separately tracks the number of accumulated genetic mutations that may confer resistance to each of the three main drug categories
More informationOr download the manual from www.crhcs.org.tz or www.fantaproject.org.
is a publication of the East, Central and Southern African Health Community Secretariat (ECSA-HC), the Food and Nutrition Technical Assistance (FANTA) Project of FHI 360, and the LINKAGES Project of FHI
More informationUK prevalence in pregnancy and risk of transmission
UK prevalence in pregnancy and risk of transmission In 2009 HIV prevalence in the UK among women giving birth was 2.2 per 1000 The majority of these women are from sub-saharan Africa with a prevalence
More informationKey Components of HIV Medical Case Management:
Key Components of HIV Medical Case Management: Treatment Adherence Prevention with Positives Updated 11/28/12 1 Treatment Adherence Counseling Every goal on the care plan must relate to HIV treatment/care.
More informationHIV Genotyping and Phenotyping
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationE4impact & Scalability
E4impact & Scalability Mario Molteni E4impact Director ALTIS Università Cattolica (Milano) 1) A case of scaling 2) A tool for scaling 1. A case of scaling 2 E4impact vision The leading Pan-African University
More informationPutting. A Product Guide for Viral Load and Point-of-Care CD4 Diagnostic Tools. www.msfaccess.org
Putting HIV Treatment to the Test A Product Guide for Viral Load and Point-of-Care CD4 Diagnostic Tools www.msfaccess.org THE MSF ACCESS CAMPAIGN In 1999, on the heels of Médecins Sans Frontières (MSF)
More informationAntiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy
Perspective Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy Antiretroviral therapy is recommended for all patients with
More informationchildren and THE GAP REPORT 2014
THE GAP REPORT 2014 children and Pregnant women LIVING WITH HIV HIV is the leading cause of death among women of reproductive age. In 2013, 54% of pregnant women in low- and middle-income countries did
More information